Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Daclatasvir | Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC 50 s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC 50 s of 1.5 μM and 3.27 μM, respectively [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BMS-790052; EBP 883. CAS No. 1009119-64-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-10466. |  |
| Daclatasvir | Daclatasvir. Group: Biochemicals. Grades: Highly Purified. CAS No. 1009119-64-5. Pack Sizes: 5mg, 10mg, 25mg, 50mg, 100mg. US Biological Life Sciences. |  Worldwide |
| Daclatasvir | Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). Synonyms: Daclatasvir; BMS-790052; BMS 790052; BMS790052; EBP-883; EBP 883; EBP883; trade name Daklinza. Grade: 0.98. CAS No. 1009119-64-5. Molecular formula: C40H50N8O6. Mole weight: 738.89. |  |
| Daclatasvir-d16 | Daclatasvir-d16 is a labelled Daclatasvir which inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). Synonyms: BMS-790052-d16; EBP 883-d16. Grade: > 95%. Molecular formula: C40H34D16N8O6. Mole weight: 754.97. | |
| Daclatasvir-d6 | Daclatasvir-[d6], is the labelled analogue of Daclatasvir. Daclatasvir, inhibits the HCV protein NS5A, and can be used in combination with other medications to treat hepatitis C (HCV). Synonyms: 1801709-41-0; Daclatasvir-d6; Melphalan Dimer-d8 Dihydrochloride; MelphalanDimer-d8Dihydrochloride; trideuteriomethyl N-[(2S)-3-methyl-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-3-methyl-2-(trideuteriomethoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate; Daclatasvir SRRS Isomer-d6; DA-62636. Grade: > 95%. CAS No. 1801709-41-0. Molecular formula: C40H44D6N8O6. Mole weight: 744.91. | |
| Daclatasvir Diethyl Ester-d10 | Daclatasvir Diethyl Ester-d10 is the isotope labelled analog of Daclatasvir Diethyl Ester (D101525); an impurity of Daclatasvir (D101500) which is a compound that inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 1mg, 5mg. Molecular Formula: C42H44D10N8O6, Molecular Weight: 776.99. US Biological Life Sciences. | Worldwide |
| Daclatasvir dihydrochloride | Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC 50 s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC 50 s of 1.5 μM and 3.27 μM, respectively [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BMS-790052 dihydrochloride; EBP 883 dihydrochloride. CAS No. 1009119-65-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-10465. | |
| Daclatasvir dihydrochloride | Daclatasvir is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Synonyms: Methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate dihydrochloride; Daclatasvir; BMS790052; BMS 790052; BMS-790052; EBP883; EBP 883; EBP-883; Daklinza. Grade: >98%. CAS No. 1009119-65-6. Molecular formula: C40H50N8O6ยท2HCl. Mole weight: 811.8. | |
| Daclatasvir Impurity 10 | Daclatasvir Impurity 10. Uses: For analytical and research use. Group: Impurity standards. CAS No. 1009119-83-8. Molecular formula: C26H29ClN6. Mole weight: 461.01. Catalog: APB1009119838. |  |
| Daclatasvir Impurity 11 | Daclatasvir Impurity 11. Uses: For analytical and research use. Group: Impurity standards. CAS No. 1007882-23-6. Molecular formula: C36H44N6O4. Mole weight: 624.79. Catalog: APB1007882236. | |
| Daclatasvir Impurity 1 (RSSS-Isomer) | Daclatasvir Impurity 1 (RSSS-Isomer). Uses: For analytical and research use. Group: Impurity standards. Alternative Names: dimethyl ((2S,2'R)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate. CAS No. 1417333-83-5. Molecular formula: C40H50N8O6. Mole weight: 738.88. Catalog: APB1417333835. | |
| Daclatasvir Impurity 1 (SRSS-Isomer) | Daclatasvir Impurity 1 (SRSS-Isomer). Uses: For analytical and research use. Group: Impurity standards. Alternative Names: Daclatasvir Impurity 1 (SRSS-Isomer). CAS No. 1009117-28-5. Molecular formula: C40H50N8O6. Mole weight: 738.88. Catalog: APB1009117285. | |
| Daclatasvir Impurity 4 | Daclatasvir Impurity 4. Uses: For analytical and research use. Group: Impurity standards. CAS No. 1009117-26-3. Molecular formula: C40H50N8O6. Mole weight: 738.89. Catalog: APB1009117263. | |
| Daclatasvir Impurity 5 | Daclatasvir Impurity 5. Uses: For analytical and research use. Group: Impurity standards. CAS No. 1009107-27-0. Molecular formula: C40H50N8O6. Mole weight: 738.89. Catalog: APB1009107270. | |
| Daclatasvir Impurity 6 | Daclatasvir SRRS Isomer is an isomer of Daclatasvir, a compound that inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). Synonyms: Daclatasvir SRRS Isomer; N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2R)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic Acid C,C'-Dimethyl Ester. Grade: > 95%. CAS No. 1009117-26-3. Molecular formula: C40H50N8O6. Mole weight: 738.88. | |
| Daclatasvir Impurity 9 | Daclatasvir Impurity 9. Uses: For analytical and research use. Group: Impurity standards. CAS No. 1007884-60-7. Molecular formula: C33H39N7O3. Mole weight: 581.72. Catalog: APB1007884607. | |
| Daclatasvir RSSR Isomer | Daclatasvir RSSR Isomer is an isomer of Daclatasvir, a compound that inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). Synonyms: Daclatasvir Impurity 4; N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1R)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic Acid C,C'-Dimethyl Ester. Grade: > 95%. CAS No. 1009107-27-0. Molecular formula: C40H50N8O6. Mole weight: 738.88. | |
| Daclatasvir RSSS Isomer | Daclatasvir RSSS Isomer is an isomer of Daclatasvir, a compound that inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). Synonyms: N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-2,1-pyrrolidinediyl[1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester stereoisomer. CAS No. 1417333-83-5. Molecular formula: C40H50N8O6. Mole weight: 738.88. | |
| 1,1'-(2S,2'S)-2,2'-(5,5'-([1,1'-Biphenyl]-4,4'-diyl)bis[1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))diethanone | 1,1'-(2S,2'S)-2,2'-(5,5'-([1,1'-Biphenyl]-4,4'-diyl)bis[1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))diethanone is derived from 5,5'-[1,1'-Biphenyl]-4,4'-diylbis[2-(2S)-2-pyrrolidinyl-1H-imidazole] Hydrochloride (B397775), which is the derivative of Daclatasvir (D101500) that inhibits the HCV protein NS5A, and thus can be used a drug candidate for the treatment of hepatitis C (HCV). Group: Biochemicals. Grades: Highly Purified. CAS No. 1447744-93-5. Pack Sizes: 10mg, 25mg. Molecular Formula: C30H32N6O2, Molecular Weight: 508.61. US Biological Life Sciences. | Worldwide |
| 1-(4'-Acetyl[1,1'-biphenyl]-4-yl)-2-bromo-ethanone | 1-(4'-Acetyl[1,1'-biphenyl]-4-yl)-2-bromo-ethanone is an intermediate/impurity towards Daclatasvir (D101500), an inhibitor of the HCV protein NS5A that may be used as a drug candidate for the treatment of hepatitis C (HCV). Group: Biochemicals. Grades: Highly Purified. CAS No. 36934-45-9. Pack Sizes: 500mg, 1g. Molecular Formula: C16H13BrO2, Molecular Weight: 317.18. US Biological Life Sciences. | Worldwide |
| [(2R,3R,4R)-3-(Benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl]methyl Benzoate | An impurity of Sofosbuvir. Sofosbuvir is a NS5B inhibtor used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir or daclatasvir. Synonyms: benzoic acid [(2R,3R,4R)-3-benzoyloxy-4-fluoro-4-methyl-5-oxo-2-oxolanyl]methyl ester; D-erythro-Pentonic acid, 2-deoxy-2-fluoro-2-methyl-, γ-lactone, 3,5-dibenzoate, (2R)-; (2R)-2-Deoxy-2-fluoro-2-methyl-D-erythro-pentonic acid γ-lactone 3,5-dibenzoate. Grade: ≥95%. CAS No. 874638-80-9. Molecular formula: C20H17FO6. Mole weight: 372.34. | |
| ((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-methyltetrahydrofuran-2-yl)methyl benzoate | An impurity of Sofosbuvir. Sofosbuvir is a NS5B inhibtor used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir or daclatasvir. Synonyms: ((2R,3R,4R,5R)-3-(benzoyloxy)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidine-1(2H)-yl )-4-methyltetrahydrofuran-2-pyridin-3-yl)methyl benzoate. Grade: 98%. CAS No. 1496551-71-3. Molecular formula: C24H21ClN2O7. Mole weight: 484.89. | |
| (2R,3R,4R,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-chloro-4-methyltetrahydrofuran-3-yl benzoate | An impurity of Sofosbuvir. Sofosbuvir is a NS5B inhibtor used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir or daclatasvir. Synonyms: (2R,3R,4R,5R)-5-(4-benzoylamino-2-oxopyrimidine-1(2H)-yl)-2-((benzoyloxy)methyl)-4-Chloro-4-methyltetrahydrofuran-3-ylbenzoate. Grade: 95%. CAS No. 1496551-70-2. Molecular formula: C31H26ClN3O7. Mole weight: 588.01. | |
| (2R,3R,4R,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-hydroxy-4-methyltetrahydrofuran-3-yl benzoate | An impurity of Sofosbuvir. Sofosbuvir is a NS5B inhibtor used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir or daclatasvir. Grade: 95%. CAS No. 863329-64-0. Molecular formula: C31H27N3O8. Mole weight: 569.56. | |
| (2S,2'S)-2,2'-([1,1'-Biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-1-pyrrolidinecarboxylic Acid 1,1'-Bis(1,1-dimethylethyl) Ester | (2S,2'S)-2,2'-([1,1'-Biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-1-pyrrolidinecarboxylic Acid 1,1'-Bis(1,1-dimethylethyl) Ester is an antiviral agent and Daclatasvir (D101500) intermediate. Daclatasvir inhibits the HCV protein NS5A and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). Group: Biochemicals. Grades: Highly Purified. CAS No. 1007882-23-6. Pack Sizes: 5mg, 10mg. Molecular Formula: C36H44N6O4, Molecular Weight: 624.77. US Biological Life Sciences. | Worldwide |
| (2S)-Isopropyl 2-(((perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate | An impurity of Sofosbuvir. Sofosbuvir is a NS5B inhibtor used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir or daclatasvir. Synonyms: Propan-2-yl (2S)-2-{[pentafluorophenoxy(phenoxy)phosphoryl]amino}propanoate; N-[(S)-(2,3,4,5,6-Pentafluorophenoxy)Phenoxyphosphinyl]-L-Alanine 1-Methylethyl Ester; N-[(S)-(2,3,4,5,6-Pentafluorophenoxy)phenoxyphosphinyl]-L-alanine1-methylethyl ester. CAS No. 1256490-52-4. Molecular formula: C18H17F5NO5P. Mole weight: 453.302. | |
| Boc-L-proline | N-Boc-L-proline is a useful synthetic intermediate. It is used to synthesize Daclatasvir which nhibits the HCV protein NS5A. Daclatasvir can be used as a drug candidate for the treatment of hepatitis C (HCV). Synonyms: Boc-L-Pro-OH; (S)-Boc-pyrrolidine-2-carboxylic acid; N-(tert-Butoxycarbonyl)-L-proline. Grade: ≥ 98% (HPLC). CAS No. 15761-39-4. Molecular formula: C10H17NO4. Mole weight: 215.30. | |
| GSK-2818713 | GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex inhibitor, GSK-2818713 exhibited picomolar potency on genotype 1 variants. Uses: The treatment of hepatitis c. Synonyms: GSK-2818713; GSK2818713; GSK 2818713. | |
| N-(Methoxycarbonyl)-L-valine | N-(Methoxycarbonyl)-L-valine is an intermidiate of daclatasvir. Synonyms: Moc-L-Valine; (S)-2-((Methoxycarbonyl)amino)-3-methylbutanoic acid; L-Valine, N-(methoxycarbonyl)-; (methoxycarbonyl)-L-valine. CAS No. 74761-42-5. Molecular formula: C7H13NO4. Mole weight: 175.18. | |
| Sofosbuvir-[13C,d3] | Sofosbuvir-[13C,d3] is the labelled analogue of Sofosbuvir. Sofosbuvir is a NS5B inhibtor used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir or daclatasvir. Synonyms: Sofosbuvir 13CD3. Grade: 95% by HPLC; 95% atom 13C; 95% atom D. CAS No. 2070009-25-3. Molecular formula: C21[13C]H26D3FN3O9P. Mole weight: 533.46. | |
| Sofosbuvir metabolite GS-566500-[13C,d3] | An isotope labelled impurity of Sofosbuvir. Sofosbuvir is a NS5B inhibtor used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir or daclatasvir. Synonyms: (2S)-2-(((((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoic-13CD3 Acid; O-Desisopropyl O-Desphenyl Sofosbuvir-13C,D3; PSI 352707-13C,D3. Grade: > 95%. CAS No. 1256490-46-6. Molecular formula: [13C]C12H16FN3O9PD3. Mole weight: 415.29. | |
Our database is helping our users find suppliers everyday.
